Can Urol Assoc J. 2025 Sep;19(9):E307-E311. doi: 10.5489/cuaj.9113. ABSTRACT INTRODUCTION: The ability of prostate-specific antigen density (PSAD) to predict metastatic disease on prostate-specific membrane antigen-positron emission tomography (PSMA-PET) at initial staging in high-risk prostate cancer (PCa) for men with negative…
Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody
Mol Imaging Biol. 2025 Aug;27(4):606-616. doi: 10.1007/s11307-025-02013-4. Epub 2025 May 22. ABSTRACT PURPOSE: Targeted radionuclide therapy against cancer stem cell-specific markers, such as CD133, constitutes a promising strategy to eliminate resilient cancer stem cells for improved outcomes in refractory tumors.…